The next two years are expected to be an important time for Zimmer Biomet's growth, CEO Ivan Tornos said in an Oct. 30 quarterly earnings call.
The company's net sales reached $1.8 billion, a 4% increase year over year. Looking ahead, Mr. Tornos said he believes that growth will remain sustainable into 2025 and 2026.
"We do believe in late 2025 and 2026 is going to be one of the major growth drivers of the company," Mr. Tornos said, as transcribed by Seeking Alpha. "Like where we are with the smart implants, it took a while to get there. But with the recent launch of the short stem, what we call Persona IQ … we're going to see meaningful adoption in 2025 and 2026.
Mr. Tornos also said there are three new indications for Rosa robotics coming up in the next two years to support the company's growth, along with coated hip devices late 2025 or early 2026.
He also touched on the Rosa shoulder robot and other orthopedic products in the works.
"You've got the stemless shoulders; you've got next-generation identity and all kinds of other products," Mr. Tornos said. "The cycle of innovation is not a one-and-done…opportunity. There are 50 new products over the next three years and a lot of them are very meaningful."